Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of blood flow obstruction in the heart, compared with those who received a placebo, according to a small study presented at the American College of Cardiology’s Annual Scientific Session (ACC.26). The trial is the first to test mavacamten in patients younger than 18. This study was simultaneously published online in the New England Journal of Medicine at the time of presentation.
This article was originally published on MedicalXpress.com
